IRS Rules State University’s Radioisotope Development with Pharma Partner Not Subject to UBIT

IRS Greenlights State University’s Radioisotope Deal with Pharma Giant, Exempting Millions from UBIT

On August 20, 2026, the IRS issued a private letter ruling (PLR-118845-25) confirming that a state university’s partnership with a biopharmaceutical firm to develop radioisotopes for life-threatening diseases does not trigger unrelated business income tax (UBIT). The ruling validates the university’s production and supply of active pharmaceutical ingredients (APIs) and research-grade isotopes under its agreement with X, finding these activities “substantially related” to its educational and scientific mission. This decision spares the university from potentially millions in UBIT liability and signals broader approval for mission-aligned academic-industry collaborations.

The ruling arrives as state universities increasingly partner with private industry to accelerate drug development while preserving tax-exempt status. Under Section 511(a)(2)(B), state colleges and universities face UBIT on income from activities not substantially related to their exempt purposes. The IRS’s determination—despite the for-profit partner—could expand academic-industry collaboration in high-stakes scientific research.

The Question: Can a State University’s Pharma Partnership Avoid UBIT?

The state university sought a private letter ruling to confirm that its development and supply of radioisotopes and APIs under a research agreement with X would not generate unrelated business taxable income (UBTI) under Section 511. The request focused on whether these activities qualified as substantially related to its exempt educational and scientific purposes under Section 513(a), thereby exempting the resulting income from UBIT.

The financial stakes were substantial. State universities increasingly collaborate with private industry to accelerate drug development while maintaining tax-exempt status. Under Section 511(a)(2)(B), state colleges and universities face UBIT on income from activities not substantially related to their exempt purposes. The IRS’s determination—despite the for-profit partner—could expand academic-industry collaboration in high-stakes scientific research. Without clarity, universities risk misclassifying millions in partnership revenue as taxable UBTI, triggering compliance burdens and penalties.

The Facts: A State University’s Mission-Driven Research Reactor

The university is a public research institution established under state law, exercising governmental powers and exempt from federal income tax under Section 115. As a state university, it is subject to UBIT under Section 511(a)(2)(B) for income from activities not substantially related to its exempt purposes. The university has not been recognized as a Section 501(c)(3) organization.

The university operates a nuclear research reactor as a constituent unit, integrated into its academic and research infrastructure. The reactor’s primary functions are education, training, and research, supporting faculty and students across disciplines including Chemistry, Veterinary Medicine, Radiology, Anthropology, Physics, and Engineering. Postdoctoral fellows and doctoral students conduct research in residence, with faculty holding joint appointments bridging academic departments and the reactor’s programs.

The reactor’s pharmaceutical research focuses on developing radioisotopes and APIs for detecting and treating life-threatening diseases like cancer. It produces research-grade isotopes and APIs and provides irradiation services to third-party customers, including for-profit companies, government entities, and academic institutions. Advanced scientific personnel—including PhD-level medicinal chemists, pharmacologists, radiologists, pharmacokinetic experts, biologists, and mechanical engineers—develop APIs.

The university entered into a development and supply agreement with X, a health care company engaged in researching, developing, manufacturing, and marketing innovative pharmaceuticals and biopharmaceuticals. The agreement is contractual and not a partnership or joint venture. Under its terms, the reactor will develop, manufacture, and supply certain APIs for X to use in its research, development, manufacturing, supply, distribution, and commercialization of a product to treat a life-threatening disease. The agreement specifies that all rights to technology owned or controlled by the reactor related to the API product will be transferred to X or its affiliates, while the reactor retains the right to manufacture, distribute, sell, and utilize the API product for non-commercial purposes, including academic research, clinical research, and clinical trials.

Before entering the agreement, the university reviewed it under its established financial policy, which permits the sale of services and products only when: (1) the service is peculiar to the nature of the department or university and necessary to the conduct of its educational, research, or service programs; (2) the provision of service contributes primarily to the convenience, comfort, health, academic, social, or recreational life of its students and staff or others participating in educational, research, or service programs; (3) the inclusion of the service improves the efficiency and economy of operations; or (4) the service is not otherwise available in the quantity or quality required or not conveniently available geographically.

The university concluded that the agreement with X met the requirements of its financial policy because it was peculiar to the nature of the reactor department and necessary to the conduct of its educational and research programs, contributed to the health, educational, and research programs of the university and the public, improved the efficiency and economy of operations, and provided services not otherwise available geographically. The university further concluded that the agreement was an indirect result of accomplishing its core mission of education and other charitable missions and not for the sole purpose of making a profit.

The IRS’s Rationale: Why the Pharma Deal Passes the 'Substantially Related' Test

The IRS analyzed the partnership under Section 511(a)(2)(B), which imposes UBIT on income from activities not substantially related to a state university’s exempt purposes. Under Section 512(a)(1), UBTI is gross income from an unrelated trade or business regularly carried on, less deductions. Section 513(a) clarifies that a trade or business is unrelated unless its conduct is substantially related to the organization’s exempt purposes—here, educational and scientific research.

The IRS applied the "substantially related" test under Treasury Regulation §1.513-1(d)(2), requiring a causal relationship between the activity and the exempt purpose. The regulation states that a trade or business is substantially related only if the production or distribution of goods or performance of services contributes importantly to the accomplishment of exempt purposes. The IRS emphasized that the API development activities must be evaluated as part of the university’s scientific research mission, not as a commercial venture.

The IRS distinguished the university’s activities from commercial operations under Treasury Regulation § 1.501(c)(3)-1(d)(5), which defines scientific research as including research carried on in the public interest and excludes activities ordinarily carried on as an incident to commercial operations. The IRS contrasted the university’s research with commercial testing, such as in Rev. Rul. 68-373, where clinical drug testing for pharmaceutical companies was deemed unrelated because it was conducted as an incident to commercial operations.

Courts have supported this distinction. In Midwest Research Institute v. United States, the court held that research performed for private sponsors did not jeopardize exempt status when the results were not published but belonged to the sponsor, except in two projects. The IRS cited this case, noting that the university’s API development involved advanced scientific expertise and was not mere routine testing. In IIT Research Institute v. United States, the court defined "scientific" as involving professional skill in designing and supervising projects to solve problems through a search for demonstrable truth, further supporting the university’s activities as scientific research.

The IRS highlighted three key facts supporting its conclusion: (1) faculty and student involvement ensured the activities contributed to the university’s educational mission; (2) advancement of public health through radioisotope development for life-threatening diseases satisfied the public interest requirement; and (3) retention of non-commercial use rights under the agreement ensured research results were not solely directed toward commercialization, aligning with Rev. Rul. 76-296.

The IRS concluded that the API development activities were scientific research, not commercial operations, because they were conducted by professionals in a research context, contributed to public health, and were integrated into the university’s educational programs. The university’s designation as a public research university by state statute further supported the finding that the activities were substantially related to exempt purposes. The IRS ruled that the income derived from the agreement was not UBTI under Section 512 and therefore not subject to tax under Section 511.

Implications: What This Ruling Means for State Universities and Research Institutions

This ruling provides critical clarity for state universities and research institutions navigating partnerships with private companies in high-stakes fields like radioisotope development and pharmaceutical research. The IRS’s determination that the university’s activities were "substantially related" to its exempt purposes hinges on three factors: mission-driven work, integration into educational programs, and the absence of profit motive in core activities. The ruling explicitly states that the income derived from the agreement was not UBTI under Section 512 and therefore not subject to tax under Section 511, reinforcing that activities advancing public health and scientific education—even with for-profit collaborators—can retain tax-exempt status.

The decision underscores the importance of aligning partnerships with an institution’s core educational and scientific missions. The IRS emphasized that the university’s designation as a public research university, combined with professional execution in a research context and contribution to public health, were decisive factors. Universities must structure agreements to ensure private-sector involvement advances research and education—not profit. Faculty and student participation, as well as integration into academic programs, strengthen the argument that the activity remains substantially related to exempt purposes.

While this ruling is non-precedential, its persuasive value is significant for institutions facing similar fact patterns. The IRS’s reasoning provides a roadmap for structuring future partnerships, demonstrating that carefully designed collaborations where private funding supports public-benefit research may avoid UBIT exposure. However, the IRS cautioned that the ruling is based on specific facts and could be revoked if those facts change.

Potential pitfalls include prioritizing profit over mission or structuring agreements without sufficient faculty and student involvement. Activities resembling commercial operations—such as those conducted primarily for revenue generation or competing with for-profit entities—risk triggering UBIT. Similarly, partnerships lacking meaningful integration into educational or research frameworks may fail the "substantially related" test. For example, licensing radioisotopes or APIs exclusively to a private company without retaining rights for further research or educational use could reclassify the income as UBTI.

To mitigate risks, universities should adopt best practices when structuring partnerships:

1. Tie private funding explicitly to research or educational outcomes, with provisions for faculty and student involvement.
2. Document how the activity furthers exempt purposes, including publications, student training, or public health benefits.
3. Frame collaborations as part of a broader research mission, avoiding structures resembling commercial product development.
4. Monitor the IRS’s evolving guidance on UBTI, particularly in emerging fields like radioisotope production and API development, where the line between exempt research and taxable commercial activity can be thin.